fda drug shortages semaglutide shortage status 2025 Expert Buying Tips,semaglutide injection product shortage has resolved

The FDA has officially declared the semaglutide shortage resolved as of February 21, 2025. This significant update marks the end of a prolonged period where semaglutide injection products, widely recognized under brand names like Ozempic and Wegovy from Novo Nordisk, experienced considerable supply constraints. The FDA's determination signifies that the current supply of semaglutide can now meet present and projected drug demand in the United States.

For a considerable time, the semaglutide shortage had been a persistent issue, impacting patients seeking treatments for type 2 diabetes and chronic weight management. The drug had been on the FDA's drug shortage list since 2022, leading to concerns about patient access and treatment continuity. However, recent FDA updates and pronouncements indicate a substantial improvement in availability, with many sources suggesting semaglutide will be off the shortage list before 2026.

The FDA's decision to remove semaglutide from the drug shortage list was formalized through a Declaratory Order issued on February 21, 2025. This order specifically addresses the semaglutide injection product shortage has resolved. This action is crucial for understanding the current status of semaglutide availability. The FDA has determined the shortage of semaglutide injection products is no longer present.

Compounding pharmacies and 503B outsourcing facilities have been operating under specific guidelines concerning semaglutide compounding. Following the FDA's announcement, 503A compounding pharmacies had until April 22, 2025, to cease compounding semaglutide injection products. Similarly, 503B outsourcing facilities had an extended deadline until May 22, 2025, to wind down their compounding of these drug products. This phased approach aims to ensure a smooth transition as the market relies more on FDA-approved semaglutide formulations.

Despite the resolution of the official drug shortage, demand for semaglutide remains exceptionally high. This sustained demand, coupled with the FDA's recent focus on unapproved GLP-1 drugs used for weight loss, has led to ongoing discussions about the true end of the shortage for some patients. Reports indicate that as of July 31, 2025, the FDA had received a significant number of adverse event reports associated with compounded semaglutide, highlighting the importance of using FDA-approved medications.

The FDA's proactive stance on drug shortages is a critical component of ensuring public health. By maintaining and updating its drug shortage list, the agency provides vital information to healthcare providers and patients. The resolution of the semaglutide shortage is a testament to the collaborative efforts between regulatory bodies and pharmaceutical manufacturers like Novo Nordisk. The FDA has effectively communicated that the semaglutide drug shortage has been resolved, and the drug is no longer on the FDA's drug shortage list.

Looking ahead, the FDA's actions, including the removal of semaglutide from its drug shortage list, signify a return to a more stable supply chain for this important class of medications. While the semaglutide shortage officially ended in early 2025, the FDA continues to monitor the market and address any emerging shortages or safety concerns related to drugs. It is important to note that tirzepatide and semaglutide shortages have been declared ended by the drug manufacturers' stated product availability. The FDA announced that the shortage of semaglutide injection products has been resolved, and semaglutide was taken off the shortage list on February 21, 2025. This marks a significant turning point, indicating that there is no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs. The FDA has declared the national semaglutide shortage "resolved" early in 2025, and semaglutide injection (Ozempic) and semaglutide injection 2.4 mg (Wegovy) is over. The semaglutide shortage status 2025 is now one of resolution, with semaglutide being removed from the drug shortage list.